AF
TLIS

Amalgamated Financial’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

Amalgamated Financial’s Portfolio TLIS Stock Details TLIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$3K Buy
+120
New +$4.15K ﹤0.01% 2982

Other funds holding TLIS

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

Amalgamated Financial's TLIS Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Talis Biomedical Corporation Common Stock (TLIS) in Q1 2022: 120 shares worth $3K. The stake represents ﹤0.01% of the portfolio and ranks #2982 among its holdings.

44 funds tracked by Wall St. Rank hold TLIS as of Q1 2022.

  • Amalgamated Financial held 120 shares of Talis Biomedical Corporation Common Stock worth $3K as of Q1 2022.
  • Talis Biomedical Corporation Common Stock was a new Amalgamated Financial position in Q1 2022.
  • Talis Biomedical Corporation Common Stock made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2982 holding.
  • 44 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.